Which has higher valuation and earnings, MBX or AURA?

MBX Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is MBX or AURA more profitable?

MBX Biosciences' return on equity of -24.52% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Aura Biosciences N/A -78.12% -64.08%

Do analysts prefer AURA or MOR?

Aura Biosciences currently has a consensus price target of $20.50, indicating a potential upside of 192.65%. Given Aura Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Aura Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AURA or MOR more profitable?

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% MorphoSys -226.79% -694.31% -22.55%

Which has better valuation and earnings, IRON or AURA?

Disc Medicine is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is IRON or AURA more profitable?

Disc Medicine's return on equity of -37.17% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Aura Biosciences N/A -78.12% -64.08%

Aura Biosciences (AURA) Competitors

$7.00 -0.01 (-0.07%)

As of 03:14 PM Eastern

Compare

AURA vs. MBX, MOR, IRON, BEAM, and ATAI

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include MBX Biosciences (MBX), MorphoSys (MOR), Disc Medicine (IRON), Beam Therapeutics (BEAM), and Atai Beckley (ATAI).

How does Aura Biosciences compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

MBX Biosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

96.8% of Aura Biosciences shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MBX Biosciences' return on equity of -24.52% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Aura Biosciences	N/A	-78.12%	-64.08%

MBX Biosciences presently has a consensus price target of $71.13, suggesting a potential upside of 9.29%. Aura Biosciences has a consensus price target of $20.50, suggesting a potential upside of 192.65%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, MBX Biosciences had 13 more articles in the media than Aura Biosciences. MarketBeat recorded 13 mentions for MBX Biosciences and 0 mentions for Aura Biosciences. MBX Biosciences' average media sentiment score of 0.85 beat Aura Biosciences' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
MBX Biosciences	Positive
Aura Biosciences	Neutral

MBX Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Summary

MBX Biosciences beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to MorphoSys?

Aura Biosciences (NASDAQ:AURA) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Aura Biosciences currently has a consensus price target of $20.50, indicating a potential upside of 192.65%. Given Aura Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Aura Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aura Biosciences' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company	Overall Sentiment
Aura Biosciences	Neutral
MorphoSys	Neutral

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
MorphoSys	-226.79%	-694.31%	-22.55%

Aura Biosciences has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aura Biosciences beats MorphoSys on 10 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Disc Medicine had 16 more articles in the media than Aura Biosciences. MarketBeat recorded 16 mentions for Disc Medicine and 0 mentions for Aura Biosciences. Disc Medicine's average media sentiment score of 0.57 beat Aura Biosciences' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Disc Medicine	Positive
Aura Biosciences	Neutral

Disc Medicine is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Disc Medicine currently has a consensus price target of $104.44, suggesting a potential upside of 37.30%. Aura Biosciences has a consensus price target of $20.50, suggesting a potential upside of 192.65%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Aura Biosciences	N/A	-78.12%	-64.08%

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Disc Medicine beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Beam Therapeutics currently has a consensus price target of $46.85, indicating a potential upside of 80.52%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 192.65%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aura Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Beam Therapeutics had 11 more articles in the media than Aura Biosciences. MarketBeat recorded 11 mentions for Beam Therapeutics and 0 mentions for Aura Biosciences. Beam Therapeutics' average media sentiment score of 1.06 beat Aura Biosciences' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Beam Therapeutics	Positive
Aura Biosciences	Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Aura Biosciences. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	16.28	-$79.99M	-$0.68	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Beam Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Beam Therapeutics beats Aura Biosciences on 12 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Aura Biosciences has lower revenue, but higher earnings than Atai Beckley. Aura Biosciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	644.97	-$660.05M	-$2.23	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

In the previous week, Atai Beckley had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Atai Beckley and 0 mentions for Aura Biosciences. Atai Beckley's average media sentiment score of 0.44 beat Aura Biosciences' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Neutral
Aura Biosciences	Neutral

Aura Biosciences has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Aura Biosciences' return on equity of -78.12% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Aura Biosciences	N/A	-78.12%	-64.08%

Atai Beckley currently has a consensus price target of $11.06, indicating a potential upside of 54.31%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 192.65%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 19.8% of Atai Beckley shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Atai Beckley beats Aura Biosciences on 9 of the 16 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$723.21M	$3.51B	$6.81B	$12.70B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.02	7.34	281.58	25.14
Price / Sales	N/A	1,195.82	571.14	79.78
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	3.24	16.87	11.03	6.20
Net Income	-$106.19M	-$12.54M	$3.48B	$347.60M
7 Day Performance	-2.16%	-0.83%	0.47%	0.81%
1 Month Performance	-9.50%	-7.59%	-4.24%	-3.65%
1 Year Performance	3.93%	48.80%	63.03%	20.30%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.0684 of 5 stars	$7.01 -0.1%	$20.50 +192.6%	+4.0%	$723.21M	N/A	N/A	50
MBX MBX Biosciences	2.102 of 5 stars	$60.06 -2.0%	$66.75 +11.1%	N/A	$2.86B	N/A	N/A	N/A
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IRON Disc Medicine	2.224 of 5 stars	$74.65 +0.1%	$104.44 +39.9%	+30.6%	$2.85B	N/A	N/A	30	Earnings Report Upcoming Earnings Analyst Upgrade
BEAM Beam Therapeutics	2.568 of 5 stars	$26.29 +4.9%	$46.85 +78.2%	+35.5%	$2.70B	$164.01M	N/A	510	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. MBX, MOR, IRON, BEAM, and ATAI

How does Aura Biosciences compare to MBX Biosciences?

Summary

How does Aura Biosciences compare to MorphoSys?

Summary

How does Aura Biosciences compare to Disc Medicine?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Summary

How does Aura Biosciences compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. MBX, MOR, IRON, BEAM, and ATAI

How does Aura Biosciences compare to MBX Biosciences?

Which has more volatility and risk, MBX or AURA?

Do institutionals & insiders have more ownership in MBX or AURA?

Is MBX or AURA more profitable?

Do analysts rate MBX or AURA?

Does the media refer more to MBX or AURA?

Which has higher valuation and earnings, MBX or AURA?

Summary

How does Aura Biosciences compare to MorphoSys?

Do analysts prefer AURA or MOR?

Does the media prefer AURA or MOR?

Is AURA or MOR more profitable?

Which has higher valuation and earnings, AURA or MOR?

Which has more volatility & risk, AURA or MOR?

Do institutionals & insiders believe in AURA or MOR?

Summary

How does Aura Biosciences compare to Disc Medicine?

Does the media favor IRON or AURA?

Which has better valuation and earnings, IRON or AURA?

Do analysts rate IRON or AURA?

Which has more volatility and risk, IRON or AURA?

Is IRON or AURA more profitable?

Do insiders and institutionals hold more shares of IRON or AURA?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Do analysts prefer BEAM or AURA?

Is BEAM or AURA more profitable?

Does the media prefer BEAM or AURA?

Do insiders and institutionals have more ownership in BEAM or AURA?

Which has stronger valuation & earnings, BEAM or AURA?

Which has more volatility & risk, BEAM or AURA?

Summary

How does Aura Biosciences compare to Atai Beckley?

Which has higher earnings and valuation, ATAI or AURA?

Does the media prefer ATAI or AURA?

Is ATAI or AURA more profitable?

Do analysts prefer ATAI or AURA?

Do insiders & institutionals believe in ATAI or AURA?

Which has more volatility and risk, ATAI or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools